Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years.
Saved in:
| Title: | Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years. |
|---|---|
| Authors: | Sabbagh M; Department of Neurology Barrow Neurological Institute Phoenix Arizona USA., Boschini C; Novo Nordisk A/S Bagsværd Denmark., Cohen S; Toronto Memory Program Toronto Ontario Canada., Fugger M; Novo Nordisk A/S Bagsværd Denmark., Jessen F; Department of Psychiatry University Hospital of Cologne Cologne Germany., Dandanell S; Novo Nordisk A/S Bagsværd Denmark., Pedersen SD; C-endo Diabetes and Endocrinology Clinic Calgary Canada., Tarazona LRS; Novo Nordisk A/S Bagsværd Denmark., Aroda VR; Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA. |
| Source: | Alzheimer's & dementia (New York, N. Y.) [Alzheimers Dement (N Y)] 2025 May 06; Vol. 11 (2), pp. e70076. Date of Electronic Publication: 2025 May 06 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley on behalf of the Alzheimer's Association Country of Publication: United States NLM ID: 101650118 Publication Model: eCollection Cited Medium: Internet ISSN: 2352-8737 (Electronic) Linking ISSN: 23528737 NLM ISO Abbreviation: Alzheimers Dement (N Y) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2352-8737 |
|---|---|
| DOI: | 10.1002/trc2.70076 |
